The Los Angeles motor scale (LAMS) and ASPECTS score are independently associated with DSA ASITN collateral score

洛杉矶运动量表 (LAMS) 和ASPECTS评分与DSA ASITN抵押品评分独立相关

Mechanical thrombectomy (MT) is the treatment standard in eligible patients with acute ischemic stroke (AIS) secondary to large vessel occlusions (LVO). Studies have shown that good collateral status is a strong predictor of MT efficacy, thus making collateral status important to quickly assess. The Los Angeles Motor Scale is a clinically validated tool for identifying LVO in the field. The aim of this study is to investigate whether admission LAMS score is also associated with the American Society of Interventional and Therapeutic Neuroradiology (ASITN) collateral score on digital subtraction angiography (DSA). Admission LAMS and ASPECTS score are both independently associated with DSA ASITN collateral score. This demonstrates the capability of LAMS to act as a surrogate marker of CS in the field.

机械取栓 (MT) 是继发于大血管闭塞 (LVO) 的急性缺血性卒中 (AIS) 患者的治疗标准。研究表明，良好的侧支状态是MT疗效的有力预测指标，因此侧支状态对于快速评估很重要。洛杉矶运动量表是一种经过临床验证的工具，用于识别该领域的LVO。这项研究的目的是调查入院LAMS评分是否也与美国介入和治疗神经放射学会 (ASITN) 在数字减影血管造影 (DSA) 上的侧支评分相关。入院LAMS和方面评分均与DSA ASITN抵押品评分独立相关。这证明了LAMS在现场充当CS的替代标记的能力。

REF: Wang R, Lakhani DA, Balar AB, et al. The Los Angeles motor scale (LAMS) and ASPECTS score are independently associated with DSA ASITN collateral score. Interv Neuroradiol. Published online October 1, 2024. doi:10.1177/15910199241282434 PMID: 39350749

Performance assessment of the Surpass Evolve flow diverter for the treatment of intracranial aneurysms: A systematic review and meta-analysis

超越进化血流导向装置治疗颅内动脉瘤的性能评估: 系统综述和meta分析

The Surpass Evolve (SE) has emerged as a promising alternative treatment from the flow diverter series. The utilization of the SE has gradually increased, however, there is a scarcity of comprehensive data on the solidity of this technology in the endovascular treatment of intracranial aneurysms (IAs). This meta-analysis aimed to evaluate the safety and effectiveness of the SE flow diverter. Our findings suggest a favorable outcome with a high rate of complete aneurysm occlusion at the last follow-up, with acceptable rates of neurological complications. Future research efforts should focus on larger, prospective studies with standardized outcome measures to further elucidate the clinical utility of the SE flow diverter in the management of IAs.

超越进化 (SE) 已成为血流导向装置系列中有希望的替代治疗方法。SE的利用已逐渐增加，但是，关于该技术在颅内动脉瘤 (IAs) 的血管内治疗中的可靠性的综合数据很少。这项荟萃分析旨在评估SE血流导向装置的安全性和有效性。我们的研究结果表明，在最后一次随访中，动脉瘤完全闭塞率高，神经系统并发症发生率可接受，结果良好。未来的研究工作应集中在具有标准化结果指标的大型前瞻性研究上，以进一步阐明SE血流导向装置在IAs管理中的临床效用。

REF: Rodriguez-Calienes A, Vivanco-Suarez J, Castillo-Huerta NM, et al. Performance assessment of the Surpass Evolve flow diverter for the treatment of intracranial aneurysms: A systematic review and meta-analysis. Interv Neuroradiol. Published online October 3, 2024. doi:10.1177/15910199241284412 PMID: 39360396

Adjunctive venous sinus stenting in transvenous embolization of vein of Galen malformations

经静脉栓塞Galen畸形静脉的辅助静脉窦支架置入术

Vein of Galen malformations are congenital arteriovenous malformations primarily treated by endovascular embolization via transarterial or transvenous approaches. transvenous embolization can be utilized to close the malformation but may be difficult in patients with venous stenosis or blockages, which drive venous hypertension and lead to significant neurologic consequences. Here, we illustrate the atypical placement of an intracranial venous sinus stent to improve outflow after transvenous embolization in pediatric patients with the vein of Galen malformation. In patients with the vein of Galen malformation and venous hypertension receiving transvenous embolization, venous sinus stenting may be a safe and effective option to reduce aberrant cortical venous drainage and improve normal outflow. Further studies are warranted to investigate its benefit in high-flow vascular malformations.

Galen静脉畸形是先天性动静脉畸形，主要通过经动脉或经静脉途径进行血管内栓塞治疗。经静脉栓塞可用于闭合畸形，但对于静脉狭窄或阻塞的患者可能很困难，这会导致静脉高血压并导致严重的神经系统后果。在这里，我们举例说明了颅内静脉窦支架的非典型放置，以改善经Galen畸形静脉的小儿患者经静脉栓塞后的流出。对于接受静脉栓塞的Galen静脉畸形和静脉高压患者，静脉窦支架置入术可能是减少异常皮质静脉引流并改善正常流出的安全有效选择。需要进一步的研究来研究其在高流量血管畸形中的益处。

REF: Devarajan A, Goldman D, Bonet J, et al. Adjunctive venous sinus stenting in transvenous embolization of vein of Galen malformations. Interv Neuroradiol. Published online October 3, 2024. doi:10.1177/15910199241282719 PMID: 39363666

Recognition of dural to pial supply in high-grade dural arteriovenous fistula: A technical note

识别高级硬脑膜动静脉瘘中的硬脑膜供应: 技术说明

High-grade dural arteriovenous fistulas (DAVFs) are known to demonstrate classical dural supply and can demonstrate pre-existing dural supply and 'pure' arterial supply from pial branches. The latter two are examples of congenital versus acquired pial to dural shunting, respectively. We describe the recognition of dural to pial supply during combined transarterial and transvenous embolization of a high-grade DAVF with holocephalic venous reflux, stressing the importance of careful assessment of this condition with micro catheter injections.

已知高级硬脑膜动静脉瘘 (davf) 可证明经典的硬脑膜供应，并且可以证明预先存在的硬脑膜供应和来自软脑膜分支的 “纯” 动脉供应。后两个分别是先天性和后天性软脑膜至硬脑膜分流的例子。我们描述了在伴有全脑静脉回流的高级DAVF的经动脉和经静脉联合栓塞过程中，硬脑膜对软脑膜供应的认识，强调了通过微导管注射仔细评估这种情况的重要性。

REF: Miyake S, Kee TP, Radovanovic I, Terbrugge K, Krings T, Hendriks EJ. Recognition of dural to pial supply in high-grade dural arteriovenous fistula: A technical note. Interv Neuroradiol. Published online October 8, 2024. doi:10.1177/15910199241272596 PMID: 39376095

Analysis of selective neurocritical care admission costs following elective endovascular treatment of unruptured intracranial aneurysms

未破裂颅内动脉瘤择期血管内治疗后选择性神经重症监护住院费用分析

No consensus exists on the necessity of neurocritical care unit (NCU)-level care following unruptured intracranial aneurysm (UIA) treatment. We aim to identify patients requiring NCU-level care post-treatment and determine potential cost savings utilizing a selective NCU admission protocol. Most patients requiring NCU-level care following UIA treatment were identified within a six-hour postoperative window. Thus, selective NCU admission for this cohort following a six-hour observation period may be a logical avenue for cost reduction. Our analysis demonstrated 5% and 13% savings for uncomplicated patients using step-down and floor admission protocols, respectively.

关于未破裂颅内动脉瘤 (UIA) 治疗后神经重症监护病房 (NCU) 级护理的必要性尚无共识。我们的目标是确定需要NCU级治疗后护理的患者，并利用选择性NCU入院方案确定潜在的成本节约。UIA治疗后需要NCU水平护理的大多数患者在术后6小时窗内被确定。因此，在六个小时的观察期之后，该队列的选择性NCU入院可能是降低成本的合理途径。我们的分析表明，分别使用降压和最低入院方案可以节省无并发症患者的5% 和13%。

REF: Roth SG, Ahn S, Liles C, et al. Analysis of selective neurocritical care admission costs following elective endovascular treatment of unruptured intracranial aneurysms. Interv Neuroradiol. Published online October 10, 2024. doi:10.1177/15910199241288880 PMID: 39387160

The Vecta 46 intermediate catheter for mechanical thrombectomy of distal medium vessel occlusions: A single-center experience

用于机械取栓远端中等血管闭塞的Vecta 46中间导管: 单中心经验

With emerging evidence supporting the clinical efficacy and safety of mechanical thrombectomy (MT) for distal medium vessel occlusions (DMVOs), MT devices specifically designed to navigate through smaller caliber and more delicate tortuous distal cerebrovasculature are required. This study describes our single-center experience using the AXS Vecta 46 intermediate catheter for first-line thromboaspiration of DMVOs. Our study demonstrates the safety and efficacy of the Vecta 46 intermediate catheter for thromboaspiration of both primary and secondary DMVOs, achieving high rates of successful recanalization and FPE.

随着越来越多的证据支持机械取栓 (MT) 治疗远端中等血管闭塞 (dmvo) 的临床疗效和安全性，需要专门设计用于导航较小口径和更精致的曲折远端脑脉管系统的MT设备。这项研究描述了我们使用AXS Vecta 46中间导管进行DMVOs一线血栓抽吸的单中心经验。我们的研究证明了Vecta 46中间导管用于原发性和继发性DMVOs的血栓抽吸的安全性和有效性，实现了高成功再通率和FPE。

REF: Choi JW, Qiao Y, Mehta TI, et al. The Vecta 46 intermediate catheter for mechanical thrombectomy of distal medium vessel occlusions: A single-center experience. Interv Neuroradiol. Published online October 14, 2024. doi:10.1177/15910199241283513 PMID: 39397490

Impact of D-dimer on the outcomes of endovascular thrombectomy for acute ischemic stroke: A systematic review and meta-analysis

D-二聚体对急性缺血性卒中血管内取栓疗效影响的系统综述和meta分析

There has been growing data about the association between D-dimer levels and thrombectomy outcomes in acute ischemic stroke patients (AIS) with no cumulative evidence. This systematic review and meta-analysis aim to discuss and analyze the findings of the current studies to provide more robust evidence in this regard. Current evidence indicates a significant association between D-dimer levels and post-thrombectomy outcomes in AIS patients. However, current data are remarkably heterogeneous, and additional comparative investigations are needed.

关于急性缺血性卒中患者 (AIS) 的D-二聚体水平与血栓切除术结果之间的关联的数据越来越多，没有累积证据。本系统综述和荟萃分析旨在讨论和分析当前研究的结果，以在这方面提供更有力的证据。目前的证据表明，AIS患者的D-二聚体水平与血栓切除术后结果之间存在显着关联。然而，目前的数据是非常不同的，需要额外的比较研究。

REF: Reda A, Ghozy S, Elfil M, Spirollari E, Gajjar A, Al-Mufti F. Impact of D-dimer on the outcomes of endovascular thrombectomy for acute ischemic stroke: A systematic review and meta-analysis. Interv Neuroradiol. Published online October 14, 2024. doi:10.1177/15910199241289628 PMID: 39400286

Safety and efficacy of newer liquid embolic agents Squid and PHIL in endovascular embolization of cerebral arteriovenous malformations and dural arteriovenous fistulas: A systematic review and meta-analysis

新型液体栓塞剂Squid和PHIL血管内栓塞脑动静脉畸形和硬脑膜动静脉瘘的安全性和有效性: 系统综述和荟萃分析

A wide range of liquid embolic agents has been used in endovascular treatment (EVT) of dural arteriovenous fistulas (dAVFs) and cerebral arteriovenous malformations (cAVMs). Newer liquid embolics, Squid (Balt) and PHIL (MicroVention), aim to improve the safety and efficacy of EVT of dAVFs and cAVMs. To assess the safety and efficacy of EVT of cAVMs and dAVFs using Squid or PHIL as an embolic agent. Squid and PHIL are safe and effective embolic agents for treatment of dAVFs and cAVMs.

广泛的液体栓塞剂已用于硬脑膜动静脉瘘 (davf) 和脑动静脉畸形 (cavm) 的血管内治疗 (EVT)。较新的液体栓塞剂Squid (Balt) 和PHIL (MicroVention) 旨在提高dAVFs和cAVMs的EVT的安全性和有效性。评估使用Squid或PHIL作为栓塞剂的cAVMs和dAVFs的EVT的安全性和有效性。Squid和PHIL是治疗dAVFs和cAVMs的安全有效的栓塞剂。

REF: Günkan A, Ferreira MY, Vilardo M, et al. Safety and efficacy of newer liquid embolic agents Squid and PHIL in endovascular embolization of cerebral arteriovenous malformations and dural arteriovenous fistulas: A systematic review and meta-analysis. Interv Neuroradiol. Published online October 17, 2024. doi:10.1177/15910199241288897 PMID: 39569607

Use of Onyx Frontier™ for intracranial stenting in stroke patients: A multicenter retrospective study

使用Onyx Frontier™卒中患者颅内支架置入术的多中心回顾性研究

Acute ischemic stroke (AIS) due to intracranial atherosclerotic disease (ICAD) carries a high risk of recurrence despite aggressive medical management. The aim of our study is to present our initial experience with the Onyx Frontier™ balloon-mounted drug-eluting stent (Medtronic, Santa Rosa, CA) for AIS due to ICAD. This is the largest multicenter cohort study demonstrating the feasibility and safety of using the Onyx Frontier™ balloon-mounted zotarolimus-eluting stent to treat symptomatic AIS due to ICAD.

尽管进行了积极的医疗管理，但由于颅内动脉粥样硬化疾病 (ICAD) 引起的急性缺血性卒中 (AIS) 仍具有很高的复发风险。我们研究的目的是介绍我们对on玛瑙前沿的初步经验™由于ICAD，用于AIS的球囊安装药物洗脱支架 (Medtronic，Santa Rosa，CA)。这是最大的多中心队列研究，证明了使用Onyx Frontier的可行性和安全性™球囊安装佐他莫司洗脱支架治疗ICAD引起的症状性AIS。

REF: Chahine A, Morsi RZ, Thind S, et al. Use of Onyx Frontier™ for intracranial stenting in stroke patients: A multicenter retrospective study. Interv Neuroradiol. Published online October 21, 2024. doi:10.1177/15910199241286922 PMID: 39429004